Article
作者: Hyrien, Ollivier ; Leav, Brett ; Hahn, William O. ; Schief, William R. ; Marini-Macouzet, Constanza ; Tomaras, Georgia D. ; McElrath, M. Juliana ; Phelps, Nicole ; Yen, Catherine ; Seese, Aaron ; Seaton, Kelly E. ; Baden, Lindsey R. ; Goepfert, Paul A. ; Furch, Briana D. ; Frank, Ian ; Stephenson, Kathryn E. ; Allen, Mary A. ; Duff, Michael O. ; Riddler, Sharon A. ; Alavi, Nushin ; Lee, Wen-Hsin ; Sobieszczyk, Magdalena E. ; Grant, Shannon ; Van Tieu, Hong ; Zheng, Zihan ; Ozorowski, Gabriel ; MacPhee, Kellie J. ; Clark, Jesse ; Laufer, Dagna S. ; Cottrell, Christopher A. ; Domin, Elize ; Heptinstall, Jack ; Ward, Andrew B. ; De Rosa, Stephen C. ; Mondal, Kajari ; Georgeson, Erik ; Cohen, Kristen W. ; Liguori, Alessia ; Keefer, Michael C. ; Kublin, James G. ; Anderson, Maija A. ; Parks, K. Rachael ; Reuter, Caroline ; Moodie, Zoe ; Montefiori, David ; Lu, Huiyin ; Walsh, Stephen R. ; Himansu, Sunny ; Kubitz, Michael ; Ballweber-Fleming, Lamar
mRNA technology might accelerate development of an urgently needed preventive human immunodeficiency virus (HIV) vaccine. We evaluated the safety and immunogenicity of three mRNA-encoded envelope trimers, including two doses of soluble and membrane-anchored forms, in a randomized, open-label, phase 1 clinical trial. Vaccines were generally well tolerated, although 6.5% (7 of 108) of participants developed urticaria, a higher proportion than seen with other mRNA vaccines. mRNA-encoded trimers induced strong envelope-specific B and T cell responses. Immunization with membrane-anchored trimers, intended to obscure epitopes at the trimer base targeted by nonneutralizing antibodies, reduced the frequency of base-binding serum antibodies in comparison with soluble trimers. Three immunizations elicited autologous tier 2 serum neutralizing antibodies in 80% of vaccinees receiving the membrane-anchored trimers, in contrast to only 4% receiving the soluble trimer. Thus, with demonstration of more favorable safety, mRNA-encoded membrane-anchored HIV envelope trimers represent a promising platform for HIV vaccine clinical development.